AN2 Therapeutics ANTX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+1.55%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AN2 Therapeutics (ANTX)
    AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.31

    • Market Cap

      $39.14 Million

    • Price-Earnings Ratio

      -0.66

    • Total Outstanding Shares

      29.88 Million Shares

    • Total Employees

      36

    • Dividend

      $0.66 Per Share Quarterly

    • IPO Date

      March 25, 2022

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      1800 el camino real, suite d, Menlo park, CA, 94027

    • Homepage

      https://www.an2therapeutics.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-61.05 Million
    Net Cash Flow, Continuing$888,000
    Net Cash Flow From Investing Activities$61.89 Million
    Net Cash Flow From Financing Activities$51,000
    Net Cash Flow From Operating Activities$-61.05 Million
    Net Cash Flow From Financing Activities, Continuing$51,000

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Operating Income/Loss$-67.00 Million
    Basic Earnings Per Share$-1.99
    Net Income/Loss Available To Common Stockholders, Basic$-60.70 Million
    Basic Average Shares$31.88 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$-34,000
    Income/Loss From Continuing Operations Before Tax$-60.70 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-60.46 Million
    Comprehensive Income/Loss$-60.46 Million
    Other Comprehensive Income/Loss$-12.51 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Accounts Payable$1.71 Million
    Current Liabilities$10.02 Million
    Noncurrent Liabilities$0
    Equity$87.67 Million
    Liabilities And Equity$97.69 Million
    Equity Attributable To Noncontrolling Interest$0

    Historical Dividends

    Current dividend: $0.66 Per Share Quarterly
    Announcement DatePayment DateRecord DateAmountFrequency
    Apr 2, 2018May 1, 2018Apr 15, 2018$0.65625Quarterly
    Sep 28, 2017Feb 1, 2018Jan 15, 2018$0.65625Quarterly
    Sep 28, 2017Nov 1, 2017Oct 15, 2017$0.65625Quarterly
    Jan 11, 2017Aug 1, 2017Jul 15, 2017$0.6562Quarterly
    Jan 11, 2017May 1, 2017Apr 15, 2017$0.65625Quarterly
    Dec 30, 2016Feb 1, 2017Jan 15, 2017$0.65625Quarterly

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ANTX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.